KURA Kura Oncology: Company Short-Term Debts

Symbol and logo of brand Kura (KURA)

Kura Oncology, Inc. (KURA) develops unique therapies for rare genetic mutations, securing a long-term market advantage through its patent system. The asset's price trajectory on this chart (separate_debt_short) is fixed at 0.01. Kura Oncology, Inc. (KURA) is implementing ESG environmental standards and strict ethical controls while simultaneously utilizing robotic systems to accelerate the analysis of molecular inhibitors during the preclinical stage.

KURA Kura Oncology Inc Company Short-Term Loans and Borrowings (07/04/2022 - 11/01/2026)

Kura - analytical breakdowns and key metrics (KURA)

- stock price and consensus target price:
Stock Price Kura Oncology|KURA - Consensus Target
- company stock capitalization data:
Market Capitalization Kura Oncology, Inc.|KURA - Total Enterprise Value
- business book valuation details:
Net Assets per Single Share Kura Oncology|KURA - Accounting Value of Company|Market Cap to Net Assets Ratio kuraoncology.com|KURA - Aggregate Asset Value
- debt and liquidity details:
Total Debt to Capital Kura Oncology, Inc.|KURA - Long-Term Debt to Equity|Short-Term Debt to Equity Kura Oncology, Inc.|KURA - Company Debts|Debt to Book Capitalization Ratio Kura Oncology, Inc.|KURA - Long-Term Debt|Company Short-Term Debt Kura Oncology|Quick Ratio kuraoncology.com
- earnings and multiples data:
KURA - Company Profit
Fundamental company valuation:KURA - Kura Oncology
Manufactured products of Kura Oncology, Inc.

Kura Oncology, Inc. (KURA) oncology drug development is independent of economic cycles, ensuring high business resilience. Analyzing short-term loan capital dynamics, an investor can see current pressure on the company's liquidity. This metric aggregates all liabilities with a maturity of up to one year based on market data. An increase in this indicator signals a risk of cash flow gaps. A reduction in the debt load confirms financial stability and increases the fair value of assets.

Main competitors

TG Therapeutics - Company Short-Term Debts|Arcellx Inc (ACLX) - Company Current Liabilities|IRON: Company Short-Term Debts|Short-Term Debt Syndax Corp (SNDX)|Company Short-Term Debt ADC Therapeutics|FHTX: Company Short-Term Loans and Borrowings|Company Current Liabilities VOR (Vor Biopharma)|NKTX (nkartatx.com) - Company Short-Term Loans and Borrowings|Company Short-Term Debts COEP (Coeptis Therapeutics, Inc.)|Actinium Corp - Company Short-Term Debt|ESLA - Company Short-Term Debt|CASI: Company Short-Term Debt|markertherapeutics.com (MRKR) - Company Short-Term Debt|Short-Term Debt IN8bio Inc. (INAB)|Company Short-Term Debt Eterna Therapeutics, Inc.|Short-Term Debt GT Biopharma Corporation GTBP|Company Short-Term Debts APTO|biopathholdings.com - Company Short-Term Indebtedness|Company Short-Term Debt MEI Pharma MEIP|Company Short-Term Debts Vincerx Pharma Inc. VINC